12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

sublingual TNX-102: Phase I started

Tonix began an open-label, Canadian Phase I trial to compare its 2.4 mg sublingual TNX-102 vs. 2.4 mg IV...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >